Default company panoramic image


Nortis provides alternatives to animal testing, based on small segments of human organs that are grown in disposable, chip-like devices.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Seattle, WA, USA
  • Currency USD
  • Founded September 2011
  • Employees 7
  • Website

Company Summary

Nortis is dedicated to developing a new generation of in-vitro assays that are based on small segments of tissues and organs grown from human-derived cells in disposable, chip-like devices. Such human “body-on-a-chip” systems represent urgently awaited alternatives to lab animals and are expected to become the 21st century gold standard for the testing of drugs, vaccines, toxic compounds, cosmetics, and warfare countermeasures.


  • Default avatar
    Thomas Neumann
    President & CEO

    Dr. Thomas Neumann is a former physician and Research Assistant Professor at the University of Washington. He has nearly ten years of experience in the biotechnology industry, with special interests in developing platforms for cancer diagnostic and microfluidic systems for reproducing tissue and organ microenvironments in vitro. He is the key inventor of Nortis’ proprietary tissue-engineering technology. Dr. Neumann received his M.D. summa cum la

  • Default avatar
    Alan C. Nelson

    Dr. Alan Nelson is a visionary entrepreneur who has launched several successful companies in the biotech sector. His first company, NeoPath, developed the first automated screening platform for cervical cancer. Dr. Nelson’s academic career path includes professor appointments at MIT, Harvard, and the University of Washington. He is the former executive director of the Biodesign Institute at ASU, where he now leads the Predictive Health Analytics

  • Default avatar
    Anna Tourovskaia
    Team Leader, Cell Biology

    Dr. Tourovskaia leads the cell biology research at Nortis. In her previous positions at the University of Washington she gained great expertise in the design and fabrication of microfluidic systems for the study of cellular functions in vitro. Her expertise lies in the investigation of biological phenomena at the micron and submicron scales, as well as in miniaturization cell culture technologies. Dr. Tourovskaia received her Ph.D. in Bioengineer

  • Default avatar
    Mark E. Fauver
    Team Leader, Engineering

    Mark Fauver is Nortis’ lead engineer and is responsible for the design and manufacture of Nortis’ microfluidic devices as well as the supporting bioreactor hardware. Mark Fauver has profound skill sets in microfabrication, imaging, automation, and software development. In his previous positions, he has designed and built several successful instruments, among them an ultra-thin endoscope and a 3D cell-imaging platform. Mr. Fauver holds a Master’s


  • Default avatar
    Richard R. Rohde (Perkins Coe)
    Default avatar
    David L. Odom (B2B CFO)